Table 3 Age, sex, and ECOG status of patients in the 12 studies evaluated in the meta-analysis
Study name (other identifier) | Sample size | Age, median (range) | Tx | Male, n (%) | ECOG status, n (%) | ||||
|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 4 | |||||
AZA-AML-001 [20] | 241 | 75 (6)a | AZA | 139 (57.7) | 54 (22.4) | 132 (54.8) | 55 (22.8) | 0 | 0 |
CALGB 11,002 [19] | 82 | 72 (61–92) | DEC | 51 (62.2) | 22 (26.8) | 41 (50.0) | 16 (19.5) | 3 (3.7) | – |
Short 2019 [21] | 28 | 77 (70–80)b | DEC 5-day | – | 18 (64.3) | – | 10 (35.7) | – | – |
43 | 78 (69–82)b | DEC 10-day | – | 30 (69.8) | – | 13 (30.2) | – | – | |
VIALE-A [6] | 145 | 76 (60–90) | AZA | 87 (60.0) | 81 (55.9) | – | 64 (44.1) | – | – |
286 | 76 (49–91) | VEN + AZA | 172 (60.1) | 157 (54.9) | – | 129 (45.1) | – | – | |
DiNardo 2018 [22] | 84 | 75 (61–90) | VEN + AZA | 51 (60.7) | 14 (16.7) | 44 (52.4) | 24 (28.6) | 2 (2.4) | – |
31 | 72 (65–86) | VEN + DEC | 15 (48.4) | 7 (22.6) | 20 (64.5) | 4 (12.9) | 0 | – | |
DiNardo 2020 [23] | 37 | 74 (69–78)b | VEN + DEC | 20 (54.1) | 26 (70.3) | – | 11 (29.7) | – | – |
Kadia 2015 [24] | 293 | – | HDAC/HMA | – | – | – | – | – | – |
Short 2020 [25] | 202 | 70 (20–90) | IDAC- or HDAC-based/HMA ± VEN | – | – | – | – | – | – |
Lindsley 2019 [26] | 156 | 68 (4)a | 7 + 3 cytarabine + daunorubicin | 96 (61.5) | – | – | – | – | – |
Prochazka 2019 [13] | 98 | 57 (20–79) | IC | 60 (61.2) | – | – | – | – | – |
Chiche 2021 [27] | 103 | 67 (20–83) | CPX-351 (daunorubicin + cytarabine) | 54 (52.4) | – | – | – | – | – |
Desoutter 2014 [28] | 96 | 73 (44–88) | AZA | – | – | – | – | – | – |